If the Nash results are as good as they are anticipated to be based on last conference call, then it will be the most substantial news for Cytodyn since hitting primary end point for HIV.
Cancer BTD will be icing on the cake. PPS will adjust accordingly. High that is. And the most important aspect of all, is credibility and reassurance that the noise behind leronlimab is validated and the drug is as amazing as it is claimed to be.
2022 is it.